Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b, Open-Label, Single-Arm Study to Evaluate the Safetyand Efficacy of CMB-012 in Subjects with Persistent Corneal Epithelial Defects (PCED)

Next Previous
Trial Profile

A Phase 1b, Open-Label, Single-Arm Study to Evaluate the Safetyand Efficacy of CMB-012 in Subjects with Persistent Corneal Epithelial Defects (PCED)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 01 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs KPI 012 (Primary)
  • Indications Chemical burns; Corneal injuries
  • Focus Adverse reactions

Most Recent Events

  • 02 Aug 2023 According to a Kala Pharamceuticals media release, Kala Pharamceuticals has changed its name to KALA BIO.
  • 04 May 2022 New trial record
  • 01 May 2022 According to a Kala Pharmaceuticals media release, Valeria Sanchez-Huerta is an investigator in this trial. Phase 1b trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top